Veltuzumab
Based on 1 Customer Validation
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.69%
- CAS. Nr.: 728917-18-8
- Molecular Weight:145.34 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD20/MS4A1
In Vitro
Veltuzumab significantly reduces off-rates in human lymphoma cell lines, as well as increases complement-dependent cytotoxicity in 1 of 3 cell lines, but no other in vitro differences[1].
Veltuzumab (0.001-10 μg/mL, 3 h) has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:4 lymphoma cell lines (SU-DHL-6, Daudi, Raji and WSU-FSCCL)
-
Concentration:5 μg/mL
-
Incubation Time:4 days
-
Result:Had the sensitivity correlated with CD20 expression (SU-DHL6> Raji > Daudi > WSU-FSCCL).
In Vivo
Veltuzumab (i.p.; 0.05-35 μg) are significantly effective in vivo[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lymphoma xenograft model[1]
-
Dosage:5, 20 and 60 μg
-
Administration:intraperitoneal and subcutaneous, single
-
Result:Showed low dose of 0.05 μg increased the MST.
-
Animal Model:SCID mice[1]
-
Dosage:0.5, 0.25, 0.1, or 0.05 μg; 35, 3.5, 0.35, or 0.035 μg
-
Administration:intraperitoneal, single
-
Result:Improved significantly survival.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD20/MS4A1 Protein, Human can bind Veltuzumab. The EC50 for this effect is 5.793 ng/mL. -
Flow Cytometry analysis of Raji cells labelling CD20/MS4A1 (red) with Veltuzumab (anti-CD20/MS4A1) (HY-P99224). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS. Nr. 728917-18-8
-
Appearance Liquid
-
Molecular Weight 145.34 kDa
-
Color Colorless to light yellow
-
SMILES
[Veltuzumab]
-
Synonyms
IMMU-106; hA20
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)